Teva Reports First Quarter 2015 Results

• Revenues of $5.0 billion, in line with the first quarter of 2014.
• Organic revenue growth of 8% excluding the impact of foreign exchange fluctuations and the divestment of the U.S. OTC plants.
• Non-GAAP operating income of $1.5 billion, an increase of 11% compared to the first quarter of 2014. GAAP operating income of $749 million, down 23%.
• Non-GAAP net income of $1.2 billion, up 11%. GAAP net income of $446 million, a decrease of 40%.
• Non-GAAP diluted EPS of $1.36, an increase of 11%. GAAP diluted EPS of $0.52, a decrease of 40%.
• Strong cash flow from operations of $1.4 billion, an increase of over 50% compared to the first quarter of 2014. Free cash flow of $1.2 billion, up 80% compared to the first quarter of 2014.
• Significant impact of exchange rates fluctuation resulted in a reduction of $368 million in revenues and $42 million in operating profit.
• Generic medicines profitability improved to 30.5%, compared to 21.0% in the first quarter of 2014. Segment profit amounted to $0.8 billion, an increase of 59% compared to the first quarter of 2014.
• On March 29, 2015, we entered into a merger agreement to acquire Auspex Pharmaceuticals, Inc., for $3.5 billion. Auspex is an innovative biopharmaceutical company specializing in applying deuterium chemistry to known molecules. Its lead investigational product, SD-809 (deutetrabenazine), is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome.
• On April 21, 2015, we announced a proposal to acquire all of the outstanding shares of Mylan N.V. in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock, representing approximately $50 billion in enterprise value. The proposed combination of Teva and Mylan would create a leading company in the pharmaceutical industry, well positioned to transform the global generics space. The combined company would have a unique and differentiated business model addressing significant trends and discontinuities prevailing today among patients and healthcare systems around the world.
• Raising EPS guidance for full-year 2015 to $5.05-5.35 from $5.00-$5.30.

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2015.

“We are extremely pleased with our performance this quarter, which is truly the manifestation of our commitment to solidifying our foundation, driving organic growth and creating the most efficient operational network in the industry. Our commitment to revitalizing our core generics business has resulted in increased revenues and profitability supported by the successful launch of generic Nexium® in the U.S.,” stated Erez Vigodman, Teva’s President and CEO. “We reinforced our leadership position in CNS with the acquisition of Auspex, where we see great promise in the application of the deuterium platform across a wide spectrum of neurological diseases and associated movement disorders; and with the continued strong performance of Copaxone 40mg® which now has a conversion rate of 67%, and maintains market leadership globally in the MS space. We are also excited about the strong performance of TEV-48125 (CGRP MAb) in our Phase IIB chronic migraine study and believe the promise shown in these trials represent significant hope for patients suffering from debilitating migraines.”

Mr. Vigodman continued, “We will continue to accelerate this momentum. Our business outlook for the remainder of the year is strong, and as such, we are raising our guidance for full year 2015 to $5.05-$5.35. We are committed to continuing to deliver significant value for shareholders in both the short and long term.”

First Quarter 2015 Results

Revenues in the first quarter of 2015 amounted to $5.0 billion, in line with revenues in the first quarter of 2014. Excluding the impact of foreign exchange fluctuations and the divestment of the U.S. OTC plants, revenues grew 8%.

Exchange rate differences (net of profits from certain hedging transactions) between the first quarter of 2015 and the first quarter of 2014 decreased our revenues by $368 million and reduced our non-GAAP operating income by $42 million and our GAAP operating income by $23 million.

Non-GAAP gross profit was $3.1 billion in the first quarter of 2015, up 2% from the first quarter of 2014. Non-GAAP gross profit margin was 61.5% in the first quarter of 2015, compared to 59.7% in the first quarter of 2014. GAAP gross profit was $2.8 billion in the first quarter of 2015, compared to $2.7 billion in the first quarter of 2014. GAAP gross profit margin was 56.9% in the quarter, compared to 53.9% in the first quarter of 2014.

Research and Development (R&D) expenditures (excluding equity compensation expenses) in the first quarter of 2015 amounted to $328 million, compared to $351 million, in the first quarter of 2014. R&D expenses were 6.6% of revenues in the quarter, compared to 7.0% in the first quarter of 2014. R&D expenses related to our generic medicines segment amounted to $111 million in the first quarter of 2015, down 10% compared to $123 million in the first quarter of 2014. In local currency terms, expenses decreased 4%. R&D expenses related to our specialty medicines segment amounted to $215 million, a decrease of 5% compared to $226 million in the first quarter of 2014, mainly as a result of our strategic focus on core therapeutic areas, including the return of rights for custirsen to Oncogenex and the divestment of certain other oncology assets.

Selling and Marketing (S&M) expenditures (excluding amortization of purchased intangible assets and equity compensation expenses) amounted to $908 million, or 18.2% of revenues, in the first quarter of 2015, compared to $963 million, or 19.3% of revenues, in the first quarter of 2014. S&M expenses related to our generic medicines segment amounted to $374 million, a decrease of 10% compared to $417 million in the first quarter of 2014. In local currency terms, S&M expenses increased 1%, as higher expenses in our ROW markets and the United States were largely offset by lower expenses in Europe. S&M expenses related to our specialty medicines segment amounted to $486 million, a decrease of 2% compared to $497 million in the first quarter of 2014. In local currency terms, S&M expenses increased 5% due to higher expenditures related to European launches, partially offset by lower expenses related to Copaxone®.

General and Administrative (G&A) expenditures (excluding equity compensation expenses) amounted to $293 million in the first quarter of 2015, or 5.9% of revenues, both the same as the first quarter of 2014.

Quarterly non-GAAP operating income was $1.5 billion in the first quarter of 2015, an increase of 11% compared to the first quarter of 2014. Quarterly GAAP operating income was $0.7 billion in the first quarter of 2015, a decrease of 23% compared to $1.0 billion in the first quarter of 2014.

Non-GAAP financial expenses amounted to $49 million in the first quarter of 2015, compared to $84 million in the first quarter of 2014. GAAP financial expenses for the first quarter of 2015 amounted to $192 million, compared to $81 million in the first quarter of 2014. The increase was mainly due to expenses of $143 million in connection with the debt tender offer and the termination of the related swap agreements.

The provision for non-GAAP tax for the first quarter of 2015 amounted to $312 million on pre-tax non-GAAP income of $1.5 billion, for a quarterly tax rate of 21%. The provision for non-GAAP tax in the first quarter of 2014 was $242 million on pre-tax non-GAAP income of $1.3 billion, or 19%. GAAP tax expenses for the first quarter of 2015 amounted to $104 million or 19% on pre-tax income of $557 million. In the first quarter of 2014, the provision for taxes amounted to $143 million or 16% on pre-tax income of $891 million.

Non-GAAP net income and non-GAAP diluted EPS were $1.2 billion and $1.36, respectively, in the first quarter of 2015, both up 11%, compared to the first quarter of 2014. GAAP net income and GAAP diluted EPS were $446 million and $0.52, respectively, in the first quarter of 2015, compared to $744 million and $0.87, respectively, in the first quarter of 2014.

Non-GAAP information: Net non-GAAP adjustments in the first quarter of 2015 amounted to $719 million. Non-GAAP net income and non-GAAP EPS for the quarter were adjusted to exclude the following items:

• Contingent consideration of $244 million, following the positive phase 2b results of TEV-48125 in both chronic and episodic migraine prevention;
• Legal settlements and loss contingencies of $227 million mainly related to the booking of an additional reserve for the settlement of the modafinil antitrust litigation;
• Amortization of purchased intangible assets totaling $220 million, of which $212 million is included in cost of goods sold and the remaining $8 million in selling and marketing expenses;
• Financial expense of $143 million;
• Impairment of long-lived assets of $65 million;
• Equity compensation of $27 million;
• Regulatory actions taken in facilities, restructuring and other expenses of $1 million; and
• Related tax benefit of $208 million.

Teva believes that excluding such items facilitates investors' understanding of its business. See the attached tables for a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures.

Cash flow from operations generated during the first quarter of 2015 amounted to $1.4 billion, compared to $0.9 billion in the first quarter of 2014. The increase was mainly due to an increase in accounts payable and lower payments related to legal settlements in the first quarter of 2015. Free cash flow, excluding net capital expenditures, amounted to $1.2 billion, compared to $0.7 billion in the first quarter of 2014.

Cash and investments at March 31, 2015 increased to $3.8 billion, compared to $2.6 billion at December 31, 2014, mainly due to proceeds from the issuance of €2 billion in senior notes in March 2015, free cash flow generated during the quarter and proceeds from exercise of options, partially offset by funding of the $1.3 billion debt tender offer, share repurchases, dividend payments and the repayment of a European Investment Bank (“EIB”) loan.

For the first quarter of 2015, the weighted average outstanding shares for the fully diluted earnings per share calculation was 859 million on both a GAAP and non-GAAP basis. At March 31, 2015, the outstanding shares for calculating Teva's market capitalization were approximately 848 million.

Shareholders’ equity was $22.7 billion at March 31, 2015, compared to $23.4 billion at December 31, 2014. The decrease primarily reflects the negative impact of $0.8 billion of currency fluctuations, share repurchases of $0.4 billion and dividend payments of $0.3 billion, partially offset by GAAP net income of $0.4 billion, $0.2 billion of net unrealized gain from derivative financial instruments and proceeds from employee stock option exercises of $0.2 billion.

Segment Results for the First Quarter 2015

Generic Medicines Segment

				Generics
				Three Months Ended March 31,
				2015						2014
				U.S.$ in millions / % of Segment Revenues
Revenues				$	2,621		100.0	%		$	2,398		100.0	%
Gross profit					1,284		49.0				1,043		43.5
R&D expenses					111		4.2				123		5.1
S&M expenses					374		14.3				417		17.4
Segment profit*				$	799		30.5	%		$	503		21.0	%

-----------------------------------------
*		Segment profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profit does not include G&A expenses, amortization and certain other items.
		Beginning in 2015, expenses related to equity compensation are excluded from our segment results. The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

Generic Medicines Revenues

Generic medicines revenues in the first quarter of 2015 amounted to $2.6 billion, an increase of 9%, or 18% in local currency terms, compared to the first quarter of 2014.

Generic revenues consisted of:

• U.S. revenues of $1.4 billion, an increase of 37% compared to the first quarter of 2014. The increase resulted mainly from the launch of esomeprazole (the generic equivalent of Nexium®) during the quarter and sales of certain other products sold in the first quarter of 2015 that were not sold in the first quarter of 2014, the most significant of which was omega-3-acid ethyl esters (the generic equivalent of Lovaza®).
• European revenues of $680 million, a decrease of 17%, or 2% in local currency terms, compared to the first quarter of 2014. The decrease in local currency terms resulted mainly from our strategy of pursuing profitable and sustainable business in the region, with significant decreases in Spain and France largely offset by increases in Italy and Germany. This strategy has continued to lead to notable improvements in the profitability of our European generics business.
• ROW revenues of $502 million, a decrease of 6%, but an increase of 11% in local currency terms, compared to the first quarter of 2014. The increase in local currency terms was mainly due to higher revenues in Latin America and Russia, which were partially offset by lower revenues in Japan and Canada.
• API sales to third parties of $157 million (which is included in the market revenues above), a decrease of 12%, or 11% in local currency terms, compared to the first quarter of 2014.

Generic medicines revenues comprised 52% of our total revenues in the quarter, up from 48% in the first quarter of 2014.

Generic Medicines Gross Profit

Gross profit from our generic medicines segment in the first quarter of 2015 amounted to $1.3 billion, an increase of 23% compared to the first quarter of 2014. Gross profit margin for our generic medicines segment in the first quarter of 2015 increased to 49.0%, from 43.5% in the first quarter of 2014. The higher gross profit was mainly a result of the launch of esomeprazole (the generic equivalent of Nexium®) in the United States and improved profitability of our European business.

Generic Medicines Profit

Our generic medicines segment generated profit of $799 million in the first quarter of 2015, an increase of 59% compared to the first quarter of 2014. Generic medicines profitability as a percentage of generic medicines revenues was 30.5% in the first quarter of 2015, up from 21.0% in the first quarter of 2014. The increase was primarily due to higher gross profit coupled with a reduction in S&M and R&D expenses.

Specialty Medicines Segment

				Specialty
				Three Months Ended March 31,
				2015						2014
				U.S.$ in millions / % of Segment Revenues
Revenues				$	1,956		100.0	%		$	2,114		100.0	%
Gross profit					1,678		85.8				1,843		87.2
R&D expenses					215		11.0				226		10.7
S&M expenses					486		24.9				497		23.5
Segment profit*				$	977		49.9	%		$	1,120		53.0	%

-----------------------------------------
*		Segment profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profit does not include G&A expenses, amortization and certain other items.
		Beginning in 2015, expenses related to equity compensation are excluded from our segment results. The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

Specialty Medicines Revenues

Specialty medicines revenues in the first quarter of 2015 amounted to $2.0 billion, a decrease of 7% compared to the first quarter of 2014. U.S. specialty medicines revenues amounted to $1.5 billion, down 3% compared to the first quarter of 2014. European specialty medicines revenues amounted to $405 million, a decrease of 16%, but an increase of 1% in local currency terms, compared to the first quarter of 2014. ROW specialty medicines revenues amounted to $72 million, down 29%, or 19% in local currency terms, compared to the first quarter of 2014.

Specialty medicines revenues comprised 40% of our total revenues in the quarter, compared to 42% in the first quarter of 2014.

The decrease in specialty medicines revenues from the first quarter of 2014 was primarily due to lower sales of Copaxone®, which were partially offset by higher revenues of our respiratory products.

The following table presents revenues by therapeutic area and key products for our specialty medicines segment for the three months ended March 31, 2015 and 2014:

				Three Months Ended March 31,						Percentage Change
				2015			2014			2015 - 2014
				U.S. $ in millions
CNS				$	1,220		$	1,413		(14%)
Copaxone®					924			1,070		(14%)
Azilect®					107			114		(6%)
Nuvigil®					85			101		(16%)
Respiratory					265			230		15%
ProAir®					124			114		9%
Qvar®					98			71		38%
Oncology					264			262		1%
Treanda®					157			180		(13%)
Women's Health					129			124		4%
Other Specialty					78			85		(8%)
Total Specialty Medicines				$	1,956		$	2,114		(7%)

Global sales of Copaxone® (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, amounted to $924 million, a decrease of 14% compared to the first quarter of 2014.

In the United States, sales of Copaxone® amounted to $732 million, a decrease of 10% compared to the first quarter of 2014. At the end of the first quarter of 2015, according to March 2015 IMS data, our U.S. market shares for the Copaxone® products in terms of new and total prescriptions were 31.9% and 30.6%, respectively. Copaxone® 40 mg/mL accounted for 66% of total Copaxone® prescriptions in the U.S. The decline in revenues mainly reflects unusually strong sales in the first quarter of 2014 due to inventory stocking in connection with the launch of Copaxone® 40 mg/mL in January 2014.

In April 2015, Sandoz announced that it had obtained final approval of its ANDA for a generic version of once daily Copaxone® 20 mg/mL. Sandoz could begin selling its generic product at any time.

Sales outside the United States amounted to $192 million, a decrease of 24%, or 10% in local currency terms, compared to the first quarter of 2014, as a result of lower volumes sold.

Our global Azilect® revenues amounted to $107 million, a decrease of 6% compared to the first quarter of 2014. In local currency terms, revenues increased 1%. Global in-market revenues decreased 6%.

Sales of our respiratory products amounted to $265 million in the first quarter of 2015, up 15% compared to the first quarter of 2014. ProAir® revenues amounted to $124 million in the first quarter of 2015, up 9% compared to the first quarter of 2014, mainly due to volume growth. In April 2015, the FDA approved ProAir® RespiClick (albuterol sulfate) inhalation powder, a breath-actuated, multi-dose, dry-powder, short-acting beta-agonist inhaler. The product is expected to become commercially available to patients in the U.S. during the second quarter of 2015.

Qvar® revenues amounted to $98 million in the first quarter of 2015, an increase of 38% compared to the first quarter of 2014, due to volume growth.

Sales of our oncology products amounted to $264 million in the first quarter of 2015, in line with results in the first quarter of 2014. Sales of Treanda® amounted to $157 million in the first quarter of 2015, a decrease of 13% compared to the first quarter of 2014. The decrease in Treanda® sales was mainly due to lower volumes caused by purchases of the newly launched liquid formulation of Treanda® in the fourth quarter of 2014, which led to higher levels of customer inventories as of December 31, 2014.

In April 2015, Eagle's NDA for a liquid bendamustine hydrochloride rapid infusion product, for which Teva has an exclusive license, was accepted for filing by the FDA. This product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval.

Specialty Medicines Gross Profit

Gross profit from our specialty medicines segment amounted to $1.7 billion in the first quarter of 2015, a decrease of 9% compared to the first quarter of 2014. The decrease was mainly the result of the lower sales of our specialty medicines.

Gross profit margin for our specialty medicines segment in the first quarter of 2015 was 85.8%, compared to 87.2% in the first quarter of 2014.

Specialty Medicines Profit

Our specialty medicines segment profit amounted to $1.0 billion in the first quarter of 2015, a decrease of 13% compared to the first quarter of 2014, mainly due to lower revenues, which were partially offset by lower S&M and R&D expenses.

Specialty medicines profitability as a percentage of segment revenues was 49.9% in the first quarter of 2015, down from 53.0% in the first quarter of 2014.

The following tables present details of our multiple sclerosis franchise and of our other specialty medicines for the three months ended March 31, 2015 and 2014:

Multiple Sclerosis
				Three months ended March 31,
				2015						2014
				U.S.$ in millions / % of MS Revenues
Revenues				$	924		100.0	%		$	1,070		100.0	%
Gross profit					819		88.6				961		89.8
R&D expenses					27		2.9				22		2.1
S&M expenses					135		14.6				165		15.4
MS profit				$	657		71.1	%		$	774		72.3	%
Other Specialty
				Three months ended March 31,
				2015						2014
				U.S.$ in millions / % of Other Specialty Revenues
Revenues				$	1,032		100.0	%		$	1,044		100.0	%
Gross profit					859		83.2				882		84.5
R&D expenses					188		18.2				204		19.5
S&M expenses					351		34.0				332		31.8
Other Specialty profit				$	320		31.0	%		$	346		33.1	%

-----------------------------------------

Beginning in 2015, expenses related to equity compensation are excluded from our franchise results. The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

Other Activities

Our OTC revenues related to PGT amounted to $212 million, a decrease of 4% compared to $220 million in the first quarter of 2014. In local currency terms, revenues increased 20%. The increase in local currency terms was mainly due to higher sales following a relatively harsh cough and cold season. PGT’s in-market sales amounted to $374 million in the first quarter of 2015, an increase of $18 million compared to the first quarter of 2014. This increase was due to higher volumes, partially offset by foreign currency exchange fluctuations.

Our revenues from OTC products in the first quarter of 2015 amounted to $213 million, compared to $269 million in the first quarter of 2014. The decline was mainly due to the sale of our U.S. OTC plants, previously purchased from P&G, back to P&G in July 2014.

Other revenues amounted to $192 million in the first quarter of 2015, mostly from the distribution of third-party products in Israel and Hungary, compared to sales of $220 million in the first quarter of 2014.

Dividend and Share Repurchase Program

The Board of Directors, at its meeting on April 28, 2015, declared a cash dividend for the first quarter of 2015 of $0.34.

The record date will be May 19, 2015, and the payment date will be June 4, 2015. Tax will be withheld at a rate of 15%.

In the first quarter of 2015, we repurchased approximately 8 million shares at a weighted average price of $57.09 per share, for an aggregate purchase price of $0.4 billion.

Conference Call

Teva will host a conference call and live webcast to discuss its results for the first quarter of 2015 and overall business environment on Thursday, April 30, 2015, at 8:00 a.m. EST. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-926-5708; Canada 1-866-925-0823; Israel 1-809-431443; or International +44(0) 1452 560304; passcode: 28107594. For a list of other international toll-free numbers, click here.

A live webcast of the call will also be available on Teva's website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until June 1, 2015, 10:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237; or International +44(0) 1452 550000; passcode: 28107594.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

The following discussion and analysis contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (including competition from orally-administered alternatives, as well as from generic equivalents such as the Sandoz product recently approved by the FDA) and our ability to migrate users to our 40 mg/mL version and maintain patients on that version; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC").

Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information contained in this report, whether as a result of new information, future events or otherwise. You are advised, however, to consult any additional disclosures we make in our reports to the SEC on Form 6-K. Also note that we provide a cautionary discussion of risks and uncertainties under “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2014. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those listed could also adversely affect us. This discussion is provided as permitted by the Private Securities Litigation Reform Act of 1995.

				Consolidated Statements of Income
				(Unaudited, U.S. dollars in millions, except share and per share data)
						Three months ended
						March 31,
						2015		2014
Net revenues						4,982		5,001
Cost of sales						2,146		2,304
Gross profit						2,836		2,697
Research and development expenses						332		353
Selling and marketing expenses						922		984
General and administrative expenses						307		302
Legal settlements and loss contingencies						227		29
Impairments, restructuring and others						299		57
Operating income						749		972
Financial expenses – net						192		81
Income before income taxes						557		891
Income taxes						104		143
Share in losses of associated companies – net						9		8
Net income						444		740
Net loss attributable to non-controlling interests						(2)		(4)
Net income attributable to Teva						446		744
Earnings per share attributable to Teva:				Basic ($)		0.52		0.88
				Diluted ($)		0.52		0.87
Weighted average number of shares (in millions):				Basic		851		850
				Diluted		859		852
Non-GAAP net income attributable to Teva:*						1,165		1,051
Non-GAAP earnings per share attributable to Teva:				Basic ($)		1.37		1.24
				Diluted ($)		1.36		1.23
Weighted average number of shares (in millions):				Basic		851		850
				Diluted		859		852
* See reconciliation attached.

					Condensed Consolidated Balance Sheets
					(U.S. dollars in millions)
					(Unaudited)
					March 31,		December 31,
					2015		2014
	ASSETS
	Current assets:
	Cash and cash equivalents				3,396		2,226
	Accounts receivable				5,508		5,408
	Inventories				4,174		4,371
	Deferred income taxes				1,181		993
	Other current assets				1,452		1,398
	Total current assets				15,711		14,396
	Other non-current assets				1,712		1,569
	Property, plant and equipment, net				6,349		6,535
	Identifiable intangible assets, net				5,243		5,512
	Goodwill				17,936		18,408
	Total assets				46,951		46,420
	LIABILITIES AND EQUITY
	Current liabilities:
	Short-term debt				1,626		1,761
	Sales reserves and allowances				5,791		5,849
	Accounts payable and accruals				3,036		3,171
	Other current liabilities				2,014		1,508
	Total current liabilities				12,467		12,289
	Long-term liabilities:
	Deferred income taxes				1,044		1,101
	Other taxes and long-term liabilities				1,372		1,109
	Senior notes and loans				9,391		8,566
	Total long-term liabilities				11,807		10,776
	Equity:
	Teva shareholders’ equity				22,636		23,313
	Non-controlling interests				41		42
	Total equity				22,677		23,355
	Total liabilities and equity				46,951		46,420

				Condensed Consolidated Cash Flow
				(Unaudited, U.S. Dollars in millions)
				Three months ended
				March 31,
				2015		2014
Operating activities:
Net income				444		740
Net change in operating assets and liabilities				557		(248)
Items not involving cash flow				353		406
Net cash provided by operating activities				1,354		898
Net cash used in investing activities				(219)		(388)
Net cash provided by (used in) financing activities				93		(634)
Translation adjustment on cash and cash equivalents				(58)		(13)
Net change in cash and cash equivalents				1,170		(137)
Balance of cash and cash equivalents at beginning of period				2,226		1,038
Balance of cash and cash equivalents at end of period				3,396		901

				Non GAAP reconciliation items
				(Unaudited, U.S. Dollars in millions)
				Three months ended
				March 31,
				2015		2014
Contingent consideration				244		(9)
Amortization of purchased intangible assets				220		285
Legal settlements and loss contingencies				227		29
Impairment of long-lived assets				65		1
Equity compensation				27		16
Costs related to regulatory actions taken in facilities				9		18
Restructuring expenses and other non-GAAP items				(8)		69
Financial expense (benefit)				143		(3)
Corresponding tax benefit				(208)		(99)

Reconciliation between reported Net Income attributable to Teva and Earnings per share
as reported under US GAAP to Non-GAAP Net Income attributable to Teva and Earnings per share
						Three months ended March 31, 2015										Three months ended March 31, 2014
						U.S. dollars and shares in millions (except per share amounts)
						GAAP		Non-GAAP Adjustments			Non-GAAP		% of Net Revenues			GAAP		Non-GAAP Adjustments			Non-GAAP		% of Net Revenues
		Gross profit (1)				2,836		226			3,062		61.5	%		2,697		291			2,988		59.7	%
		Operating income (1)(2)				749		784			1,533		30.8	%		972		409			1,381		27.6	%
		Net income attributable to Teva (1)(2)(3)				446		719			1,165		23.4	%		744		307			1,051		21.0	%
		Earnings per share attributable to Teva - Diluted (4)				0.52		0.84			1.36					0.87		0.36			1.23
(1)		Amortization of purchased intangible assets						212										268
		Costs related to regulatory actions taken in facilities						9										18
		Equity compensation						3										1
		Other COGS related adjustments						2										4
		Gross profit adjustments						226										291
(2)		Contingent consideration						244										(9	)
		Legal settlements and loss contingencies						227										29
		Impairment of long-lived assets						65										1
		Equity compensation						24										15
		Restructuring expenses and other non-GAAP items						(10	)									65
		Amortization of purchased intangible assets						8										17
								558										118
		Operating income adjustments						784										409
(3)		Financial expense						143										(3	)
		Tax benefit						(208	)									(99	)
		Net income adjustments						719										307

(4)		The weighted average number of shares was 859 million and 852 million for the three months ended March 31, 2015 and 2014, respectively. Non-GAAP earnings per share can be reconciled with GAAP earnings per share by dividing each of the amounts included in footnotes 1-3 above by the applicable weighted average share number.
*		Beginning in 2015, expenses related to our equity compensation are excluded from our non-GAAP results.
		The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

					Segment Information
				Generics
				Three months ended March 31,												Percentage Change
				2015						2014						2015 - 2014
				U.S.$ in millions / % of Segment Revenues
Revenues				$	2,621		100	%		$	2,398		100.0	%		9	%
Gross Profit					1,284		49.0	%			1,043		43.5	%		23	%
R&D Expenses					111		4.2	%			123		5.1	%		(10	%)
S&M Expenses					374		14.3	%			417		17.4	%		(10	%)
Segment Profit*				$	799		30.5	%		$	503		21.0	%		59	%
				Specialty
				Three months ended March 31,												Percentage Change
				2015						2014						2015 - 2014
				U.S.$ in millions / % of Segment Revenues
Revenues				$	1,956		100	%		$	2,114		100.0	%		(7	%)
Gross Profit					1,678		85.8	%			1,843		87.2	%		(9	%)
R&D Expenses					215		11.0	%			226		10.7	%		(5	%)
S&M Expenses					486		24.9	%			497		23.5	%		(2	%)
Segment Profit*				$	977		49.9	%		$	1,120		53.0	%		(13	%)

* Segment profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Beginning in 2015, expenses related to our equity compensation are excluded from segment results.

The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

				Additional information
				Multiple Sclerosis
				Three months ended March 31,													Percentage Change
				2015						2014							2015 - 2014
				U.S.$ in millions / % of MS Revenues
Revenues				$	924		100.0	%		$	1,070		100.0	%			(14	%)
Gross profit					819		88.6	%			961		89.8	%			(15	%)
R&D expenses					27		2.9	%			22		2.1	%			23	%
S&M expenses					135		14.6	%			165		15.4	%			(18	%)
MS profit				$	657		71.1	%		$	774		72.3	%			(15	%)
				Other Specialty
				Three months ended March 31,													Percentage Change
				2015						2014							2015 - 2014
				U.S.$ in millions / % of Other Specialty Revenues
Revenues				$	1,032		100.0	%		$	1,044		100.0	%			(1	%)
Gross profit					859		83.2	%			882		84.5	%			(3	%)
R&D expenses					188		18.2	%			204		19.5	%			(8	%)
S&M expenses					351		34.0	%			332		31.8	%			6	%
Other Specialty profit				$	320		31.0	%		$	346		33.1	%			(8	%)

Beginning in 2015, expenses related to our equity compensation are excluded from our franchise results.

The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

Reconciliation of our segment profit
to Teva's consolidated income before income taxes
				Three months ended March 31,
				2015			2014
				U.S.$ in millions
Generic medicines profit				$	799		$	503
Specialty medicines profit					977			1,120
Total segment profit					1,776			1,623
Profit of other activities					50			51
Total profit					1,826			1,674
Amounts not allocated to segments:
Amortization					220			285
General and administrative expenses					307			302
Impairments, restructuring and others					299			57
Legal settlements and loss contingencies					227			29
Other unallocated amounts					24			29
Consolidated operating income					749			972
Financial expenses - net					192			81
Consolidated income before income taxes				$	557		$	891

Beginning in 2015, expenses related to our equity compensation are excluded from segment results.

The data presented have been conformed to reflect the exclusion of equity compensation expenses for all periods.

Revenues by Activity and Geographical Area
(Unaudited)
						Three Months Ended March 31,						Percentage Change			Percentage Change
					2015			2014				2015 - 2014			2015 - 2014
					U.S. $ in millions										in local currencies
Generic Medicines
	United States				$	1,439		$	1,048			37	%		37	%
	Europe*					680			818			(17	%)		(2	%)
	Rest of the World					502			532			(6	%)		11	%
Total Generic Medicines						2,621			2,398			9	%		18	%
Specialty Medicines
	United States					1,479			1,530			(3	%)		(3	%)
	Europe*					405			482			(16	%)		1	%
	Rest of the World					72			102			(29	%)		(19	%)
Total Specialty Medicines						1,956			2,114			(7	%)		(3	%)
Other Revenues
	United States					3			51			(94	%)		(94	%)
	Europe*					182			207			(12	%)		6	%
	Rest of the World					220			231			(5	%)		9	%
Total Other Revenues						405			489			(17	%)		(3	%)
Total Revenues					$	4,982		$	5,001			§			7	%

* All members of the European Union, Switzerland, Norway, Albania and the countries of former Yugoslavia.

§ Less than 0.5%.

		Revenues by Product line
		(Unaudited)
		Three Months Ended March 31,						Percentage Change
		2015			2014			2015 - 2014
		U.S. $ in millions
Generic Medicines		$	2,621		$	2,398		9	%
API			157			179		(12	%)
Specialty Medicines			1,956			2,114		(7	%)
CNS			1,220			1,413		(14	%)
Copaxone®			924			1,070		(14	%)
Azilect®			107			114		(6	%)
Nuvigil®			85			101		(16	%)
Respiratory			265			230		15	%
ProAir®			124			114		9	%
Qvar®			98			71		38	%
Oncology			264			262		1	%
Treanda®			157			180		(13	%)
Women's Health			129			124		4	%
Other Specialty			78			85		(8	%)
All Others			405			489		(17	%)
OTC			213			269		(21	%)
Other Revenues			192			220		(13	%)
Total		$	4,982		$	5,001		§

§ Less than 0.5%.

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Iris Beck Codner, 972 (3) 926-7246
or
United States
Denise Bradley, 215-591-8974

Source: Teva Pharmaceutical Industries Ltd.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Progress Software Corporation (PRGS) Issues Statement on a Possible Offer for MariaDB
• Vaxxinity, Inc (VAXX) to Voluntarily Delist
• Crown Castle (CCI) Issues Statement on "Ted Miller's Latest Attempt to Disrupt the Company's Momentum"